Vascular Biogenics (VBLT) – Recent investment analyst rating changes


Vascular biogenics (NASDAQ: VBLT ) has recently received a number of price target changes and ratings updates:

  • 7/20/2022 – Vascular Biogenics was downgraded by analysts at Chardan Capital from a “buy” rating to a “neutral” rating.
  • 7/20/2022 – Vascular Biogenics was downgraded by analysts at HC Wainwright from a “buy” rating to a “neutral” rating.
  • 7/20/2022 – Vascular Biogenics was downgraded by analysts at Oppenheimer Holdings Inc. from an “outperform” rating to a “market perform” rating.
  • 7/18/2022 – Vascular Biogenics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
  • 7/18/2022 – Vascular Biogenics was reaffirmed by analysts at Oppenheimer Holdings Inc. for its “best” rating.
  • 7/10/2022 – Vascular Biogenics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
  • 7/2/2022 – Vascular Biogenics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
  • 6/24/2022 – Vascular Biogenics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
  • 6/16/2022 – Vascular Biogenics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
  • 6/8/2022 – Vascular Biogenics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
  • 5/31/2022 – Vascular Biogenics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.

Vascular biogenics stock performance

Shares of VBLT opened at $0.25 on Tuesday. The stock has a market cap of $17.35 million, a P/E ratio of -0.54 and a beta of 1.09. The firm has a 50-day simple moving average of $1.55 and a 200-day simple moving average of $1.50. Vascular Biogenics Ltd. it has a 52-week low of $0.24 and a 52-week high of $2.54.

Vascular Biogenics (NASDAQ:VBLT – Get Rating ) last posted its earnings results on Tuesday, May 17th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). Vascular Biogenics had a negative net margin of 4,894.40% and a negative return on equity of 69.21%. The business had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.20 million. During the same quarter last year, the firm earned ($0.12) earnings per share. Sell-side analysts predict that Vascular Biogenics Ltd. will post -0.51 EPS for the current year.

Hedge funds weigh in on vascular biogenics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Advisor Group Holdings Inc. raised its stake in shares of Vascular Biogenics by 49.2% in the first quarter. Advisor Group Holdings Inc. now owns 36,797 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 12,133 shares in the last quarter. Envestnet Asset Management Inc. acquired a new position in Vascular Biogenics during the first quarter worth about $64,000. DLD Asset Management LP lifted its position in Vascular Biogenics by 29.4% during the first quarter. DLD Asset Management LP now owns 550,000 shares of the biopharmaceutical company’s stock valued at $930,000 after buying an additional 125,000 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. acquired a new position in Vascular Biogenics during the 4th quarter valued at about $382,000. Finally, Lion Point Capital LP acquired a new position in Vascular Biogenics during the 4th quarter worth about $5,108,000. Institutional investors own 26.15% of the company’s shares.

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immuno-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology that targets newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables the specific inhibition of monocyte migration for immuno-inflammatory applications.

Featured stories



Get daily news and reviews for Vascular Biogenics Ltd – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Vascular Biogenics Ltd and related companies with MarketBeat.com ‘s FREE daily email newsletter.

Leave a Comment

Your email address will not be published.